

**In-depth characterisation of the $Alms1^{foz/foz}$
mouse model of Alström syndrome**

**A THESIS SUBMITTED IN TOTAL FULFILMENT
OF THE REQUIREMENTS OF
THE DEGREE OF DOCTOR OF PHILOSOPHY**



**FLINDERS
UNIVERSITY**

**ADELAIDE
AUSTRALIA**

Dorothee Angélique Gaëlle Girard

**Department of Diabetes and Endocrinology
School of Medicine, Flinders University
Adelaide, South Australia**

July 2012

Table of contents

List of figures	iv
List of tables	vii
Thesis summary	viii
Declaration	xi
Acknowledgements	xii
Publications and Seminars	xiv
Awards	xvi
Abbreviations	xvii
Chapter 1 : Introduction	1
1. Genetics of AS	2
2. Clinical features of Alström syndrome.....	6
2.1. Primary symptoms	6
2.2. Other features.....	7
2.3. Diagnosis	9
3. AS is a new ciliopathy	11
3.1. Ciliopathy Classification	11
3.2. Structure of the primary cilium	17
3.3. Primary cilium function.....	18
3.4. AS: a new “model” ciliopathy	19
4. Animal models of AS	20
5. Postulations on Alms1 protein function	28
6. Therapy of AS.....	35
7. Conclusions	38

8. Research aims and plan	39
Chapter 2 : Characterisation of early onset insulin resistance in	
Alms1^{foz/foz} mice	41
1. Abstract.....	42
2. Introduction.....	43
3. Material and methods	45
4. Results	50
5. Discussion.....	77
Chapter 3 : NOD/Alms1^{foz/foz} mice are protected against both	
spontaneous and cyclophosphamide-induced Type 1 Diabetes Mellitus	
.....	80
1. Abstract.....	81
2. Introduction.....	82
3. Material and Methods.....	84
4. Results	89
5. Discussion.....	106
Chapter 4 : Characterisation of cognitive impairment in Alms1^{foz/foz}	
mice and axonal transport of Alms1 protein	109
1. Summary.....	110
2. Introduction.....	111
3. Material and Methods.....	113
4. Results	119
5. Discussion.....	135

Chapter 5 : Alms1^{foz/foz} chromaffin cells display reduced secretory activity but unaltered exocytosis 138

1. Summary 139

2. Introduction..... 140

3. Material and Methods 141

4. Results 145

5. Discussion..... 151

Chapter 6 : Perspectives..... 153

References..... 160

List of figures

Figure 1-1: Human ALMS1 gene and Alms1 protein schematic	5
Figure 1-2: Mouse ALMS1 gene structure and <i>foz</i> deletion schematic.....	21
Figure 1-3: The “Fat Aussie” AS mouse model	23
Figure 1-4: Postulated function of Alms1 protein	31
Figure 2-1: Body weight record and ITT screening in 6 month old <i>Alms1^{foz/foz}</i> mice	53
Figure 2-2: ITT screening in 6 month old <i>Alms1^{foz/foz}</i> mice fed with high fat diet	55
Figure 2-3: Fasting glycemia and IPGTT screening in 6 month old <i>Alms1^{foz/foz}</i> mice	57
Figure 2-4: Body weight and ITT screening in young <i>Alms1^{foz/foz}</i> males....	60
Figure 2-5: Body weight and ITT screening in young <i>Alms1^{foz/foz}</i> females.	63
Figure 2-6: Body weight and IPGTT screening in young <i>Alms1^{foz/foz}</i> mice	65
Figure 2-7: Fasting parameters and HOMA-IR scoring in young <i>Alms1^{foz/foz}</i> males.....	67
Figure 2-8: Fasting parameters and HOMA-IR scoring in young <i>Alms1^{foz/foz}</i> females.....	69
Figure 2-9: Endogenous insulin response following glucose challenge in young <i>Alms1^{foz/foz}</i> mice	71
Figure 2-10: <i>Alms1^{foz/foz}</i> mouse adipocyte morphology.....	73
Figure 2-11: Insulin pathway proteins screening by Western blot on 6 month old non-fasted <i>Alms1^{foz/foz}</i> insulin sensitive tissues	76

Figure 3-1: Obesity and insulin resistance monitoring in NOD/FA mice ...	92
Figure 3-2: Cumulative T1DM incidence in the female NOD/FA cohort ..	94
Figure 3-3: Histopathology of pancreatic β -islets by H&E staining	96
Figure 3-4: Fasting blood insulin and HOMA-IR scoring in 250 days old NOD/FA mice	98
Figure 3-5: Effect of RD on insulin resistance in NOD/Alms1 ^{foz/foz} mice .	101
Figure 3-6: Effect of RD on fasting blood insulin and HOMA-IR scoring in NOD/Alms1 ^{foz/foz} mice	103
Figure 4-1: Young Alms1 ^{foz/foz} mice average body weight and swim speed	119
Figure 4-2: Young Alms1 ^{foz/foz} mice latency during the training sessions .	121
Figure 4-3: Young Alms1 ^{foz/foz} mice memory assessment during the probe test.....	123
Figure 4-4: 6 month old FA mice body weight and swim speed.....	124
Figure 4-5: 6 month old Alms1 ^{foz/foz} latency during the training sessions .	125
Figure 4-6: 6 month old Alms1 ^{foz/foz} mice memory assessment during the probe test.....	127
Figure 4-7: Alms1 ^{foz/foz} mice brain weight comparison at 60 days and 6 months of age.....	129
Figure 4-8: Congo red staining of brain sections.....	131
Figure 4-9: Bi-directional axonal transport of Alms1 protein.....	132
Figure 4-10: The axonal trafficking is not disrupted in Alms1 ^{foz/foz} condition.	134

Figure 5-1: Amperometry recording traces and number of exocytotic events	147
Figure 5-2: Fusion pore kinetics parameters of exocytotic events	150
Figure 6-1: Alms1 function research focus in the insulin signalling pathway	156

List of tables

Table 1-1: Diagnostic criteria for Alström syndrome.....	10
Table 1-2: Ciliopathies with their respective OMIM number and gene(s) involved	12
Table 1-3: Ciliopathies classified as having both structural and metabolic defects.....	14
Table 1-4: Ciliopathies classified as having both structural and developmental defects	15
Table 1-5: Ciliopathies classified as having structural defects.....	16
Table 3-1: Effect of diet and CY on T1DM incidence in >250 days old NOD/FA mice.....	105

Thesis summary

Monogenic causes of obesity and type 2 diabetes mellitus (T2DM) include Alström syndrome (AS). AS belongs to an interesting new class of disorders called ciliopathies, which have a common origin in gene mutations causing dysfunction of an important cellular organelle known as the primary cilium. AS is inherited as an autosomal recessive disorder caused by a mutation in the *ALMS1* gene that leads to an extensive clinical phenotype encompassing childhood metabolic disorders, retinal degeneration, sensorineural deafness, cardiomyopathy and infertility. Thus, research into ciliopathies including AS represents an exciting novel focus in a wide range of research fields including endocrinology and neurosciences.

The “Fat Aussie” (FA) mouse or *Alms1^{f_{oz}/f_{oz}}* is a model for AS that carries a spontaneous deletion (*f_{oz}*) in the exon 8 of the *ALMS1* gene. The *Alms1^{f_{oz}/f_{oz}}* mouse recapitulates the disorders occurring in AS patients and represents a unique opportunity to further characterise the pathogenic mechanisms underlying ciliopathy-associated obesity, insulin resistance and T2DM. The metabolic phenotyping study of *Alms1^{f_{oz}/f_{oz}}* mice has revealed that early peripheral insulin resistance is an inherent primary consequence of the *ALMS1* gene disruption at a time that β -cell function isn't affected. Insulin resistance may thereby drive the subsequent metabolic complications in the *Alms1^{f_{oz}/f_{oz}}* mouse model. Outcomes from this study also suggest that the defect leading to insulin resistance in *Alms1^{f_{oz}/f_{oz}}* mice

must be downstream of AS160 phosphorylation in the insulin pathway and might concern either the translocation of GLUT4 or its recycling.

Female NOD/*Alms1^{foz/foz}* mice were then used as a new model to investigate the intricate relationship between metabolic disturbances such as obesity and T2DM and the onset of type 1 diabetes mellitus (T1DM). Surprisingly, NOD/*Alms1^{foz/foz}* mice were protected against T1DM. Data showed that β cell destruction was significantly suppressed in NOD/*Alms1^{foz/foz}* mice which had intact hyperplastic β -islets, limited immune cell infiltration and unaltered insulin secretory capacity. Thus, metabolic disturbances in NOD/*Alms1^{foz/foz}* mice may paradoxically inhibit the development of T1DM.

New features, which have not been described before in AS mouse models, have been highlighted in this project. *Alms1^{foz/foz}* mice displayed early mild cognitive impairment worsening with age suggesting defective neuronal function. The axonal transport of *Alms1* protein further suggests a possible involvement of *Alms1* in neuronal protein trafficking. Neuroendocrine chromaffin cells from *Alms1^{foz/foz}* mice showed a reduced exocytosis rate but unimpaired pore fusion kinetics. Together, these data suggest a possible involvement of the *Alms1* protein in neuronal signalling and vesicle trafficking.

This project has helped to better characterise the underlying defects that drive the FA mouse model of AS to multi-organ pathology by finding clues

to Alms1 protein function. Research into unravelling Alms1 protein function should not only lead to improved treatments for patients with AS, but also provide a better understanding of cellular pathways involved in more common disorders such as obesity and T2DM.

Declaration

‘I certify that this thesis does not incorporate without acknowledgement any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.’

Dorothée Angélique Gaëlle Girard

Acknowledgements

First I would like to thank my supervisor, Prof. Nikolai Petrovsky who has given me the opportunity to undertake this PhD project. Thanks for the helpful guidance, constructive scientific discussions and setting challenging goals.

I am also grateful to Prof Xin-Fu Zhou and Dr. Damien Keating for supervising my work in neuroscience and cell signalling field. Thanks for sharing your expertise and helping me extend my scientific knowledge.

I thank Dr Tim Chataway for his advice and help in proteomics and Dr Jennifer Clarke for her invaluable expertise and assistance in microscopy. A big thanks to Samuel Richie who has made my work life easier by taking excellent care of our mouse colonies.

In addition, I want to give a huge thank you my co-workers for their invaluable help, support and friendship. Thank you Samay Trec for the assistance in animal work and all the time you have spent writing animal ethics. Thanks Alyshea Collaco for your help in histology and microscopy work. I am also grateful to Dr Yoshikazu Honda for sharing his scientific knowledge and supervising my immunology related work. Thank you David Simon Davis, Wendy King, Margaret Menadue, Dr Nicholas Kasmeridis,

Dr Lei Li, Dr Charlotte LeLan, Dr Fadi Saade and John Zhuang for great moments shared during this PhD journey.

I don't forget my friends back in France who have also been very supportive during the past 4 years. I have missed you a lot.

Last but not the least; I would like to thank my parents and my brother for their constant love and support. Thanks for believing in me, supporting my choices and giving me the strength to always move forward.

This thesis is dedicated to my grandparents Yvonne, Xavier and Albert.

Publications and Seminars

Review

1. **Dorothee Girard** and Nikolai Petrovsky. Alström syndrome: insights into the pathogenesis of metabolic disorders. *Nature Reviews Endocrinology* 7, 77–88 (2011).

Conference abstracts arising from this thesis

1. **Dorothee Girard**, Nikolai Petrovsky. Investigation of Alms1 protein function using the “Fat Aussie” mouse model of human Alström syndrome. Workshop: “France and South Australia – Current Joint Activities in Science & Technology and Future Directions for Cooperation”. The South Australian Department of the Premier and Cabinet and the Embassy of France in Australia, Adelaide, 24th July 2009. Oral presentation.
2. **Dorothee Girard**, Nikolai Petrovsky. Increased insulin resistance compounded by reduced insulin sensitivity drives the Fat Aussie ($Alms1^{foz/foz}$) model of Alström syndrome towards obesity and type 2 diabetes mellitus. Cilia 2012 conference – Cilia in Development and Disease, London, 17-18th May 2012. Poster presentation.

Other conference abstracts

1. **Dorothee Girard**, Linyan Wu, Christian Schoenbach, Nikolai Petrovsky. Novel translational frameshift mechanism contributing to genome complexity. Adelaide Immunology Retreat, Annual event of the Australasian Society for Immunology (ASI), Normanville, 12th-13th Sept 2008. Oral presentation.
2. **Dorothee Girard**, Michelle Lui, Nikolai Petrovsky. Obesity-associated impaired vaccine responsiveness in *Alms1^{foz/foz}* mice is compensated by a novel polysaccharide adjuvant. Medical research week, SA scientific meeting, Australian Society for Medical Research (ASMR), Adelaide, 2nd June 2009. Oral presentation.

Awards

1. Immune Strategies Area of Strategic Research Investment (ASRI) Postgraduate Scholarship (1st July 2008-30th June 20).
2. Seeding Grant 2008, Faculty of Health Sciences Research Grants 2008, Flinders University.
3. Finalist of the 2009 AusBiotech-GSK student excellent awards South Australia with the project “Obesity-associated impaired vaccine responsiveness in $Alms1^{foz/foz}$ mice is compensated by a novel polysaccharide adjuvant.”

Abbreviations

5HT6	5-hydroxytryptamine receptor 6
ABR	Auditory brain response
AGRP	Agouti-related protein
AS	Alström syndrome
AS160 (or TBC1D4)	Akt Substrate of 160 kDa
ARC	Arcuate nucleus
AU	Arbitrary unit
BBS	Bardet-Biedl syndrome
BDNF	Brain-Derived Neurotrophic Factor
BMI	Body mass index
bp	Base pair
CART	Cocaine and amphetamine related transcript
C/EBP- α	CCAAT/enhancer-binding protein alpha
CNS	Central nervous system
CPE	Carboxypeptidase E
CY	Cyclophosphamide
DAPI	Diamidino-2-phenylindole
DCM/CHF	Dilated cardiomyopathy with congestive heart failure
EGF	Epidermal growth factor
ER	Endoplasmic reticulum
ERG	Electroretinogram
FA	Fat Aussie mouse strain

GAPDH	Glyceraldehyde 3-phosphate dehydrogenase
GH	Growth hormone
GLP	Glucagon like peptide
Glut 4	Glucose transporters 4
H&E	Hematoxylin and eosin
HFD	High fat diet
HOMA	Homeostatic model assessment
IFT	Intraflagellar transport
IGF	Insulin-like growth factor
INPP5E	Inositol polyphosphate-5-phosphatase E
IPGTT	Intraperitoneal glucose tolerance test
IR	Insulin resistance
IRAP	Insulin-regulated aminopeptidase
IRS1	Insulin receptor substrate 1
ITT	Insulin tolerance test
JS	Joubert syndrome
KLH	Keyhole Limpet Hemocyanin
KRPH	Krebs Ringer Phosphate Hepes
Mb	Megabase
MCHR1	Melanin concentrating hormone receptor 1
MCP	Macrophage chemoattractant proteins
MDCK	Madin-Darby canine kidney
MJ	Megajoule

MORM	Mental retardation, truncal obesity, retinal dystrophy and micropenis
NA	Not applicable
ND	Normal diet
NOD	Non obese diabetic
NPY	Neuropeptide Y
NS	Not significant
Nt	Nucleotide
OMIM	Online Mendelian Inheritance in Man
p75NTR	p75 neurotrophin receptor
PEI	Polyethylenimine
PBS	Phosphate buffered saline
PBST	Phosphate buffered saline with Tween 20
PKD	Polycystic kidney disease
POMC	Proiomelanocortin
RD	Restricted diet
RFX	Regulatory factor X
RNA	Ribonucleic acid
RP	Retinitis pigmentosa
RT	Room temperature
SC	Subcutaneous
SEM	Standard error of the mean
Shh	Sonic hedgehog
SNAP	Synaptosomal associated protein

SSTR3	Somatostatin receptor 3
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus
UTI	Urinary tract infection
VR2	Vasopressin receptor 2
WAT	White adipose tissue
WT	Wildtype